# Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Source: https://onco.cc/trials/nct00057811/  
OnCo record `nct00057811` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Doxorubicin, Cyclophosphamide, Methotrexate, Rasburicase, Leucovorin, Prednisone, Filgrastim, Rituximab, Cytarabine, Etoposide and Vincristine in Burkitt lymphoma and Acute lymphoblastic leukaemia, run by Children's Oncology Group, completed.

## Summary

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma is a phase 2 interventional study registered as NCT00057811 by Children's Oncology Group, with 97 participants recorded, started 2004-06 and reaching its primary completion in 2009-10. Interventions recorded: doxorubicin hydrochloride, cyclophosphamide, methotrexate, rasburicase, leucovorin calcium, prednisone, methylprednisolone, filgrastim, rituximab, cytarabine, etoposide, vincristine sulfate, hydrocortisone sodium succinate, laboratory biomarker analysis. Conditions recorded: Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Untreated Childhood Acute Lymphoblastic Leukemia.

Linked to the drug Rasburicase because the registry names it among its interventions and Burkitt lymphoma and Acute lymphoblastic leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00057811
- Phase: 2
- Setting: A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy
- Sponsor: Children's Oncology Group
- Enrolled: 97

## Sources

- ClinicalTrials.gov NCT00057811: https://clinicaltrials.gov/study/NCT00057811

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Burkitt lymphoma](https://onco.cc/cancers/burkitt-lymphoma/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Cytarabine](https://onco.cc/drugs/cytarabine/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Methotrexate](https://onco.cc/drugs/methotrexate/), [Prednisone](https://onco.cc/drugs/prednisone/), [Rasburicase](https://onco.cc/drugs/rasburicase/), [Rituximab](https://onco.cc/drugs/rituximab/), [Vincristine](https://onco.cc/drugs/vincristine/)

---
JSON: https://onco.cc/api/v1/entities/nct00057811.json